The recent emergence of immunotherapy has marked a sea change in research and care for many forms of cancer, bringing new hope to patients and families around the world. For those who respond to treatment, the results can ...
Apr 9, 2019
0
39
Stereotactic Body Radiotherapy (SBRT), a high-dose, precisely delivered radiotherapy, is considered the standard treatment for patients with medically inoperable, node-negative, non-small cell lung cancer (NSCLC). However, ...
Apr 5, 2019
0
0
By any measure, lung cancer patients have it rough.
Mar 21, 2019
0
0
Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer ...
Mar 20, 2019
0
27
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study published in the journal Radiology: Artificial Intelligence.
Mar 20, 2019
0
0
Brazilian researchers have discovered that a drug regularly prescribed to control cholesterol can also be used to treat cachexia, or wasting syndrome, a condition characterized by rapid weight loss and muscle atrophy associated ...
Mar 20, 2019
0
13
Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...
Feb 26, 2019
0
0
Immune cells called T cells are key components in the fight against cancer. However, they sometimes struggle to recognize cancerous cells or to launch an appropriate response against them. T cell activity can be tweaked to ...
Feb 22, 2019
0
16
Small spots on CT scans of the lungs of children with muscle cancer do not have an adverse effect on survival, according to an international research team in the Journal for Clinical Oncology. This conclusion has direct consequences ...
Feb 15, 2019
0
9
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing the level of programmed death ligand 1 (PD-L1) expressed by ...
Feb 13, 2019
0
1
